Sales of the popular Type 2 diabetes drug metformin may get a boost if physicians begin prescribing the medicine as a prophylactic in people who don’t have diabetes. A recent study published in the diabetes journal Diabetes, Obesity and Metabolism and conducted by scientists from Cardiff University found that patients treated with metformin could live longer than people without diabetes.
Dick Tracy has nothing on the wearable gadgets under development to help people better police their diabetes. Wearable technologies in its totality — which include Google Glass and the Apple Watch — are part of a booming market that’s expected to swell to $20 billion by 2015 and is further expected to grow at a compound annual growth rate of nearly 40% over the next six years.
Close to half (40%) of the U.S. adult population — roughly 126 million — is expected to develop Type 2 diabetes at some point during their lifetime, according to a study published in The Lancet Diabetes and Endocrinology in August.
Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system.
The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.